Vendor Intelligence Report: Pharma Grade Peptides

Published 13 Jun 2026. 27-page investigative report on who is behind Pharma Grade Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Pharma Grade Peptides is not a simple pass/fail vendor story. Across 18 Finnrick lab tests the overall pass rate is 17% (3 pass / 15 fail). The signal is sharply uneven: GHK-Cu is the only tested line with a favorable relative read, while BPC-157 and CJC-1295 are switch-away signals; middle cases remain fail-heavy and compress under stricter grading.

The identity file is weaker than the brand language. The site claims a 2018 founding and pharmaceutical-grade positioning, but domain and archive records begin later. The Terms name MLL as operator, California searches found no matching filing, and the US addresses are commercial mailboxes rather than verified facilities.

Domain forensics create a major authentication problem: the evaluated plural .is domain has a UAE registrant handle, while a near-identical singular .is storefront is tied to Hong Kong records and makes a conflicting official-site claim. Reviews split between removed/low Trustpilot visibility and high Shopper Approved checkout-stage ratings; a Janoshik BPC-157 COA does not substantiate GMP, sterility, endotoxin control, or the unfavorable independent BPC-157 tests.

The buyer read is directional: no direct FDA warning-letter or recall action was found by name, but that does not offset product-test and identity risk. Pharma Grade Peptides may be defensible only where fresh independent batch evidence is favorable; for BPC-157/CJC-1295 buyers, vendor COAs, coupon pages, and irreversible Bitcoin checkout deserve extra caution.

Inside the full report:

  • Appendix A: per-product pass/fail rates, trajectories, and methodology-divergence charts for all 9 tested products
  • Corporate identity exhibits: MLL Terms, California no-results capture, and mailbox-address analysis
  • Domain timeline: older .com, UAE-registered plural .is, and Hong Kong-registered singular lookalike with conflicting official-site claims
  • Janoshik BPC-157 COA assessment against GMP, sterility, endotoxin, and batch-verification gaps
  • Review and promotion analysis covering Trustpilot, Shopper Approved, coupon pages, Reddit, BTCPay, and the BlueFitMD lead

Risk assessment

  • Product-specific quality risk — high: Finnrick record is 18 tests (3 pass / 15 fail); GHK-Cu is the only clean tested product, while BPC-157 and CJC-1295 are especially weak (0/2 each, 43.15% and 22.34%).
  • Corporate identity and physical-presence opacity — high: Terms name operator only as 'MLL'; no California filing found for Pharma Grade Peptides/MLL, and the listed Fontana/Philadelphia addresses are commercial mailboxes.
  • Brand-confusion / copycat-domain risk — high: pharmagradepeptides.is and lookalike pharmagradepeptide.is make conflicting official-site claims; no authoritative channel/reseller list or anti-counterfeit verification was found.
  • Reputation and fulfillment complaint risk — high: Trustpilot main profile was removed; .net profile shows 2.4/5 with 77% one-star reviews alleging non-delivery, fake tracking, spoilage, and double charging.
  • COA/GMP-substantiation risk — medium: Janoshik BPC-157 COA is present, but supplied materials do not show batch-verifiable order details or GMP, sterility, endotoxin, or residual-solvent testing.
  • Affiliate-promotion and regulatory-adjacent marketing risk — medium: Scan found poorly disclosed code/coupon placements and a field lead into BlueFitMD's FDA-cited peptide marketing network; no direct PGP FDA action was found.